Sanofi ADR
I · Analyse IA
En bref
Sanofi researches, manufactures, and markets a broad portfolio of medicines and vaccines, including pediatric vaccines (polio, pertussis, hepatitis), immunology treatments, rare disease therapies, and cancer drugs [Company Overview]. The company operates through partnerships with biotech firms to develop next-generation therapies using AI, protein degradation, and genome editing technologies [Company Overview].
Sanofi is a major French pharmaceutical company with $104,3 billion market cap that develops and sells vaccines, immunology treatments, rare disease therapies, and oncology drugs [Yahoo Finance]. Recent positive phase 2 trial results for efdoralprin alfa in a rare lung disease and AI investments in Alzheimer's research show R&D momentum, though the stock dropped 9% over the past month [Yahoo Finance]. The company is financially healthy with $10,1 billion in free cash flow and a 5,55% dividend yield [Yahoo Finance].
Sanofi is financially healthy with strong cash generation and manageable debt levels [Yahoo Finance].
Score Sentinellis
7,4/10
Préoccupations modérées
Capitalisation boursière
$104,3B
Chiffre d'affaires (12 mois)
EUR 46,7B
Explications
Comment nous lisons ces chiffres
Guides en langage clair · sans compte
ROIC vs WACC Explained: How to Tell If a Company Actually Creates Value
What ROIC and WACC are, how to compute both, and why the spread between them is the single most important number in fundamental investing.
LirePiotroski F-Score Explained: A 9-Point Financial Health Check (with a Live Apple Example)
What the Piotroski F-Score is, how to calculate all 9 criteria, and how to read the result. Plain English, with a real Apple walkthrough.
LireAltman Z-Score Explained: Predicting Bankruptcy in 5 Minutes (with Real Examples)
What the Altman Z-Score is, the exact formula, how to read the result, and which version to use for manufacturers vs tech vs private companies.
LireII · Actualités récentes
Ce qui a fait bouger le cours
5 articles · classés par pertinence
- Macro2026-05-18
Kernicterus Market Research and Forecast Report 2026-2036 Featuring Pfizer, F.Hoffmann La Roche,. Merck, AbbVie, AsteraZeneca, Abbott Laboratories, Sanofi, GlaxoSmithKline, Grifols
Yahoo Finance
- Macro2026-05-18
Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
Yahoo Finance
- Macro2026-05-18
A Look At Sanofi (ENXTPA:SAN) Valuation After Recent Share Price Weakness
Simply Wall St
- Macro2026-05-18
Sanofi Deepens AI And Alzheimer’s Research While Shares Trade Below Targets
Simply Wall St
- Macro2026-05-19
Sanofi: Information concerning the total number of voting rights and shares - April 2026
Yahoo Finance
Premium · gratuit avec tout compte
The stock dropped 9% over the past month and has struggled over the past year, signaling investor concern about near-term performance despite longer-term gains [Simply Wall St]
Risques
5
Opportunités
6
Signaux d'alerte
2
Direction
10
12 autres constats dans le rapport complet — gratuit avec tout compte.
Débloquer l'analyse complète de Sanofi ADR
Créez un compte gratuit pour accéder au rapport complet généré par IA, avec les sources citées dans le texte.
- 5 risques, 6 opportunités et 2 signaux d'alerte — chacun avec sa source
- Plus de 100 indicateurs financiers avec graphiques et comparaisons
- Résumés d'actualités complets avec liens vers les sources
- Équipe dirigeante et rémunération
III · Entreprises similaires
À lire également
Même secteur · Santé — ou santé financière comparable
L'ajouter à votre liste ?